Healthcare System, authored a guest editorial 1 entitled "It's Time to Clean Up <797>." The editorial, while noting that there are redeeming aspects to the USP <797> standards, asked that pharmacists' voices be heard regarding aspects of the USP regulations that are not based on peerreviewed evidence. It also asked regulatory bodies to shift their focus toward adherence to aseptic technique and quality assurance measures rather than compliance with standards that may not be based on best evidence. I would like to state again that the patient safety efforts of the standards are laudable and there should be standards for sterile compounding. USP was solicited to respond and, although USP could not respond directly to the editorial, provided the following information.
In the editorial, readership feedback was also requested from hospital pharmacists on the USP standards. Although we could not publish all of the feedback that Hospital Pharmacy received, a representative sample is included along with a response from Michael Sanborn. I would like to thank all who responded and again entreat feedback on the standards, both positive and negative. Being a practitioner-focused journal with the salient focus of patient safety, Hospital Pharmacy would like to provide a balanced forum for discussion of this topic. E-mails may be sent to Dennis.Cada@wolterskluwer.com.
-Dennis J. Cada, PharmD, FASHP, FASCP Editor-in-Chief Hospital Pharmacy
USP RESPONSE
USP appreciates the opportunity to provide this information for readers of Hospital Pharmacy regarding the current public standard relating to pharmaceutical compounding and sterile preparations.
Growing concerns about the quality of compounded preparations led the USP Sterile Compounding Expert Committee to issue USP General Chapter <797> Pharmaceutical Compounding -Sterile Preparations in USP 29-NF 24, which became official on January 1, 2004, and the subsequent proposed revisions to this General Chapter in Pharmacopeial Forum 32(3), May-June 2006, for public review and comment.
Public input and interaction are vital to the development of USP's Standards. Comments from interested parties on proposed revisions to the USP-NF help the Expert Committees understand the potential impact of standards on the relevant communities, to understand how the proposed standards should be refined, and to ensure that the standards will help to protect the public health.
USP took steps to make the proposed revisions to General Chapter <797> available to health care practitioners for their input, beyond publication in the Pharmacopeial Forum, USP's primary method of public notice and comment. The proposed revisions are still available on the USP Web site, www.usp.org. USP provided briefings to interested professional organizations and presented Internet-based seminar, ("webinars") on the proposed revisions throughout the comment period. USP also published a guidebook to the proposed revisions containing additional information to assist in understanding the proposal.
We believe that our efforts to reach health care practitioners were successful. We have received approximately 550 comments from more than 300 hospitals, professional associations, vendors, stakeholders, and individual health care practitioners. These comments are of great value as the Expert Committee works toward finalizing the revision.
Comments reflect both concerns and praise for the work of the Committee. It is encouraging to know that practitioners and other stakeholders are willing to take the time to provide positive comments and make suggestions for improvement for this General Chapter.
The USP Sterile Compounding Expert Committee currently is reviewing and considering all comments received during the comment period, which ended on August 15, 2006. Due to the volume and substance of these comments, it is difficult to determine when a final revision will be completed. Certain revised sections of the General Chapter could be released with the next USP-NF publication in November 2007, which becomes official on May 1, 2008. Certain sections will require the guidance of Advisory Panels, which are being formed to provide extra informational and experiential expertise in specific topics covered by General Chapter <797>. USP staff and members of the Sterile Compounding Expert Committee thank all who have commented on General Chapter <797>, and assure practitioners that we always welcome comments on our public standards.
READER RESPONSES
■ Thank you for the excellent editorial in Hospital Pharmacy, November 2006. As a pharmacy consultant to four rural hospitals in Northern Nevada, I have been actively involved in USP <797> facility reviews, analysis, and design. I have reviewed several facilities in Nevada and Texas, implementing clean room design changes, developing policies and procedures, and training pharmacy staff in aseptic technique.
The critical component lacking in the proposed USP <797> regulations is peer-reviewed, evidencebased medicine for these regulations. As the cornerstone of Western medicine, evidence-based data to support the proposed regulations must exist. Though I have not reviewed all the literature regarding the proposed regulations, those I have reviewed are not based upon scientific evidence. Why then are we all trying to comply with regulations that are not supported by scientific evidence?
As you mention in the editorial, aseptic technique is the critical step in the process. Our efforts should be directed to implementing appropriate policies and procedures to validate technique, not necessarily the environment. We need to have our professional organizations request evidence-based medical documentation for the proposed regulations before they are implemented. The Nevada State Board of Pharmacy has worked diligently with all provider segments to draft state regulations that appropriately parallel USP <797>.
I would be very interested in assisting in the process to ensure regulations are based upon medical evidence rather than the exaggerated response to infectious consequences in US hospitals identified by the Joint Commission invested approximately $100,000 in the conversion of our IV into a clean room. Since that time, we have also invested additional dollars in gowns, caps, shoe covers, and cleaning materials such as specialized floor cleaners to maintain this "clean" environment. Ironically, we have not seen any change in our infection rates or in the quality control test results we perform. As Mr. Sanborn states in his article, the focus of the regulations should be on appropriate training of aseptic technique, annual competency testing, and overall quality assurance testing. The majority of smaller (200 beds or less) independent hospitals are currently faced with serious financial concerns and cannot afford to indulge in unnecessary expenses for which there is no scientific proof of benefit. More disturbing than the fact that these regulations have been allowed to proceed this far is that truly effective patient safety initiatives such as increasing clinical pharmacy programs and bar coding are being postponed because the dollars are being spent to comply with <797>.
- resources solely for the purpose of adherence to environmental standards that were baseless. Even when evidence exists to the contrary, this doesn't stop many who may profit from selling their 'wares' based on regulatory mandates. Attention and resources should be concentrated on those areas that have demonstrable safety outcomes as those described in Mr. Sanborn's editorial.
I don't believe in not doing something just because it is too hard to do. JCAHO has been criticized for the lack of scientific evidence to support the promotion of their National Patient Safety Goals, to which adherence is mandatory for accreditation. However, there have been deaths and significant harm directly linked to the use of abbreviations, verbal orders, concentrated electrolytes, etc. That is why I support those goals. There is nothing to directly link the environment outside a class 100 LAFH (lower anterior face height) to contaminated products.
My hope is that this editorial will spark a much-needed and long-overdue debate as to the merits of the USP <797> standards and clearly set a new course towards rational, evidence-based standards that actually improve safety. My fear, justifiably so, is that all of this regulatory nonsense will lead to patient harm.
-Mark Thomas, MS, RPh Director of Pharmacy Cook Children's Medical Center Fort Worth, TX ■ I read with great interest the editorial "It's Time to Clean Up <797>." I couldn't agree more! This is a tremendous drain of national health care resources that could be much better spent elsewhere to effect real improve-ments. As far as I know, there is absolutely no evidence showing that what is going on in the environment outside a Class 100 (ISO Class 5) hood in any way affects the quality of the product. As pointed out in the editorial, the quality of the person operating inside the Class 100 environment is what determines the product quality, and that is where the money should be spent if we are going to improve patient safety. I am glad to see someone finally speak out on this issue! Hopefully, in the near future, we can bring some sense of logic and reasoning to the table and base Chapter <797> on evidence-based requirements that really would improve product quality and patient safety. Thank you for speaking out.
-James R. Fenno, RPh Director of Pharmacy Chippewa Falls, WI ■ There is nothing that our colleague writes that I can disagree with. I approached the USP about the make-up requirement and could not obtain any information as to why this decision was made. I pointed out that if the issue was shedding from the make-up, then a full face shield would seem appropriate, which is what we are doing. Nowhere in the hospital is it mandated that staff members are not allowed to wear make-up, including the OR. I do not want to lose a staff member over this issue. Additionally, USP <797> has not addressed needs outside of pharmacy. At my facility, an IV set can be used for up to 48 hours. Pharmacy expends the effort to produce the appropriate product, only to have nursing use a set in open air with no restrictions on the number of times that set can be removed from one bag and inserted into another for two days; and that may include the ubiquitous technique of the nurse using her/his teeth to remove the spike cover before insertion the first time.
Every hospital pharmacist knows that nosocomial infections are on the rise and that MRSA is rampant. Action is needed. We need to be putting our money and energy into changes that make more sense and can offer the greatest results. It is my hope that leadership from ASHP will be able to work with the USP and the JCAHO to achieve a more holistic approach to sterile compounding that is doable. Much of USP <797> is not doable in most pharmacies. I know of no pharmacy that is truly compliant.
Additionally, I would comment that glove boxes have not been the answer. It is far more difficult to maintain proper technique when working in a glove box. Also, since we all come in different shapes and sizes, workers' comp issues (ie, strained backs and necks) are becoming an issue. The glove boxes could become expensive trash and that money could be used more wisely.
Finally, USP <797> needs to somehow move into physicians' offices, where surgery centers and infusion centers are run outside of the JCAHO. Physicians' offices or physician-run centers where admixtures are done should somehow be held to the same standards as hospitals for the sake of our patients.
-Billy Cooper, RPh, DOP Cartersville Medical Center Cartersville, GA AUTHOR RESPONSE I appreciate the overwhelmingly supportive response generated by the editorial that the above sampling represents. Further, I am heartened by USP's suggestion of the formation of Advisory Panels that will provide "extra informational and experiential expertise," as this seems to be the key component that was missing from the original regulations and proposed revisions. I strongly encourage USP to populate these panels with pharmacists that are currently practicing in hospitals and health systems rather than just microbiologists, scientists, researchers, and consultants.
There are several elements raised by the responses that deserve additional comment and consideration. References to the negative impact that the standards have had on rural and critical access hospitals without any corresponding improvement to patient care are important points. The environmental mandates in the standard and requisite capital outlays are quite costly and difficult to absorb for facilities already burdened with limited financial resources. There are also significant operational and personnel costs associated with <797> compliance. Such expenditures have likely delayed or prevented much more meaningful and evidencebased patient safety improvements.
Comments related to admixture compounding in non-hospital settings, the make-up requirement, and the issue surrounding hospital tubing changes and bag spiking practices are also relevant and worthy of additional deliberation. There definitely appears to be a double standard. Another salient point is that glove boxes are cumbersome, time consuming, and have the potential to create significant employee fatigue and injury challenges. There is also limited information on their use in hospital settings, since relatively few if any hospitals used them prior to the publication of the <797> regulations. A final concern raised is the possible unintended consequence of the standards leading to reduced product quality due to the false sense of security created by a clean room environment.
In response to the one negative letter received from McAteer, the author seems to miss the entire point of the editorial and cites only one of the many arguments presented. I in no way question the science behind USP <51>, but to make the systematic leap that these manufactured product standards should also apply to hospital-based compounding is inappropriate. I believe every hospital pharmacist supports the use of evidence-based, beyond-use dating and this is a very fitting and worthwhile component of the <797> regulations. The author directly compares hospital compounding with manufacturing, demonstrating a lack of understanding between the two settings and the obvious differences in intended use, shelf-life goals, and necessary regulatory requirements.
The fundamental fact remains that there is not one published research article demonstrating that the compounding environment (beyond an ISO Class 5 hood) within hospitals has any bearing on product quality or sterility. There is evidence suggesting that the external environment is meaningless, and the key to quality is proper aseptic technique. I again restate that where evidence is not available, studies should be conducted and pertinent <797> regulations should be reclassified as guidelines until such trials prove the need for added regulation. 
